Scarica l'app Stockscreener
45.68
1.78%
-0.83
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$46.51
Aprire:
$46.04
Volume 24 ore:
19.86M
Relative Volume:
1.28
Capitalizzazione di mercato:
$154.86B
Reddito:
$46.69B
Utile/perdita netta:
$15.29B
Rapporto P/E:
13.31
EPS:
3.4329
Flusso di cassa netto:
$9.25B
1 W Prestazione:
-7.64%
1M Prestazione:
-22.60%
6M Prestazione:
-32.38%
1 anno Prestazione:
-57.56%
Intervallo 1D:
$45.15
$46.27
Intervallo di 1 settimana:
$45.15
$49.90
Portata 52W:
$45.05
$112.52
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
45.68 | 206.67B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
924.37 | 839.03B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.57 | 450.47B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
219.16 | 387.13B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.35 | 242.86B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
86.28 | 212.91B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump - The Motley Fool
Novo Nordisk ADR earnings missed by $0.09, revenue fell short of estimates - Investing.com
Can Novo Nordisk A s (b Shares) Adrhedged stock rebound after recent weaknessRecession Risk & Real-Time Volume Triggers - fcp.pa.gov.br
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates - Investing.com South Africa
Will Novo Nordisk A s (b Shares) Adrhedged stock gain from strong economyExit Point & Trade Opportunity Analysis - fcp.pa.gov.br
Wegovy maker Novo Nordisk cuts guidance again but Medicare pricing deal uplifts investors - The Globe and Mail
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates By Investing.com - Investing.com Nigeria
$NVO Last opportunity! for NYSE:NVO by alexei_erchov - TradingView
Bengals-Bears game today: Chicago Bears outlast Cincinnati Bengals for wild 47-42 win on Williams' TD pass to Loveland - ABC7 Chicago
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' - Sahm
Will Novo Nordisk A s (b Shares) Adrhedged stock deliver strong dividend growthExit Point & Smart Investment Allocation Tips - fcp.pa.gov.br
Can Novo Nordisk A s (b Shares) Adrhedged stock outperform in 2025 bull marketJuly 2025 Chart Watch & Fast Momentum Entry Tips - fcp.pa.gov.br
P/E Ratio Insights for Novo Nordisk - Sahm
Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk - Sahm
Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail
Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail
Multi asset correlation models including Novo Nordisk A s (b Shares) Adrhedged2025 Big Picture & Accurate Entry and Exit Point Alerts - newser.com
J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Novo Nordisk Stock Is Falling Friday: What's Driving The Action? - Sahm
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? - Sahm
Trump’s Ozempic pledge is nothing new, says Nordnet economist - medwatch.com
Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032 - Sahm
What's Driving the Market Sentiment Around Novo Nordisk AS? - Sahm
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem - Sahm
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' - Sahm
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Sahm
Novo Nordisk layoffs: Pharma major begins job cuts in US amid fierce weight-loss drug battle — Here's what we know - livemint.com
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Why Is Scholar Rock Stock Trading Lower On Monday? - Sahm
Does Novo Nordisk’s Latest Drug Trial Setback Signal a Chance for Investors in 2025? - Sahm
Deutsche Bank Remains a Buy on Novo Nordisk (0QIU) - The Globe and Mail
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.70%
1.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):